Dr. Greg Licholai is a Special Advisor focused on clinical transformation and healthcare data strategy. He is Chief Medical Officer and Chief Innovation Officer, and President of Symphony Health at ICON plc. Dr. Licholai is on the faculty of Yale School of Management, Co-Director of the Center for Digital Health and teaches Innovating Healthcare at Harvard Business School. Previously, he was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. He was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates, and was co-founder of Immunome Therapeutics.
Dr. Licholai attended Harvard Business School, Yale School of Medicine, Columbia University and Boston College. He trained in Neurological Surgery at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals. He serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). Dr. Licholai writes about innovation in healthcare for Forbes, contributed to Digital Therapeutics Strategic, Scientific, Developmental, and Regulatory Aspects contributed to Digital Therapeutics Strategic, Scientific, Developmental, and Regulatory Aspects and his textbook Introduction to Medical Software: Foundations for Digital Health, Devices and Diagnostics is published by Cambridge University.